Nikolai A. Podoltsev

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation

Neil Romberg, Khatoun Al Moussawi, Carol Nelson‐Williams et al. · Nature Genetics · 2014 · 510 citations · Full text

Medicine, Immunology, Infectious Diseases +10

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

Hagop M. Kantarjian, Gail J. Roboz, Patricia Kropf et al. · The Lancet Oncology · 2017 · 154 citations · Full text

Medicine, Hematology, Pharmacology +6

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018

Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia et al. · Journal of the National Comprehensive Cancer Network · 2017 · 151 citations · Full text

Medicine, Hematology, Oncology +15

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Maximilian Stahl, Michelle DeVeaux, Pau Montesinos et al. · Blood Advances · 2018 · 149 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15